Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
2011 1
2012 1
2015 1
2016 1
2020 1
2021 2
2022 1
2023 49
2024 243

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year

Filters applied: . Clear all
Page 1
Aromatase Inhibitors.
Peters A, Tadi P. Peters A, et al. 2023 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32491779 Free Books & Documents.
Anastrozole is a medication used in the management and treatment of breast cancer. It is in the aromatase inhibitors class of drugs. This activity describes the indications, action, and contraindications for anastrozole as a valuable agent in managing advanced hormo …
Anastrozole is a medication used in the management and treatment of breast cancer. It is in the aromatase inhibitors class of …
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T, Hortobagyi G. Slamon D, et al. N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488. N Engl J Med. 2024. PMID: 38507751 Clinical Trial.
METHODS: In this international, open-label, randomized, phase 3 trial, we randomly assigned patients with HR-positive, HER2-negative early breast cancer in a 1:1 ratio to receive ribociclib (at a dose of 400 mg per day for 3 weeks, followed by 1 week off, for 3 years) plus a nons …
METHODS: In this international, open-label, randomized, phase 3 trial, we randomly assigned patients with HR-positive, HER2-negative early b …
Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs.
Janowska S, Holota S, Lesyk R, Wujec M. Janowska S, et al. Molecules. 2024 Jan 10;29(2):346. doi: 10.3390/molecules29020346. Molecules. 2024. PMID: 38257259 Free PMC article. Review.
Aromatase inhibitors can be classified into two main groups based on their chemical structure: steroidal and non-steroidal inhibitors. This work presents a review of the literature from the last ten years regarding the search for new aromatase inhib …
Aromatase inhibitors can be classified into two main groups based on their chemical structure: steroidal and non-steroidal …
CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety.
Wekking D, Lambertini M, Dessì M, Denaro N, Bardanzellu F, Garrone O, Scartozzi M, Solinas C. Wekking D, et al. Semin Oncol. 2023 Dec;50(6):131-139. doi: 10.1053/j.seminoncol.2024.01.002. Epub 2024 Jan 13. Semin Oncol. 2023. PMID: 38245458 Free article. Review.
The development of oral cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib, has revolutionized the treatment landscape for patients with hormone-receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2 …
The development of oral cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib, has …
Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer.
Bahnassy S, Stires H, Jin L, Tam S, Mobin D, Balachandran M, Podar M, McCoy MD, Beckman RA, Riggins RB. Bahnassy S, et al. Endocrinology. 2023 Nov 2;164(12):bqad159. doi: 10.1210/endocr/bqad159. Endocrinology. 2023. PMID: 37897495
In the present study, we developed and characterized 2 in vitro models of ET-resistant (ETR) HER2+/ER+ BCa to identify possible therapeutic vulnerabilities. To mimic ETR to aromatase inhibitors (AIs), we developed 2 long-term estrogen deprivation (LTED) cell lines f …
In the present study, we developed and characterized 2 in vitro models of ET-resistant (ETR) HER2+/ER+ BCa to identify possible therapeutic …
Design and Pharmacophore Study of Triazole Analogues as Aromatase Inhibitors.
Banjare L. Banjare L. Anticancer Agents Med Chem. 2024;24(4):288-303. doi: 10.2174/0118715206265278231026101739. Anticancer Agents Med Chem. 2024. PMID: 37921212
BACKGROUND: In current scenario breast cancer measured as one of the dangerous health issues. An effective therapeutic class of drug known as aromatase inhibitors (AIs) is dominant against estrogen receptorpositive breast cancer. ...OBJECTIVES: In the present study, …
BACKGROUND: In current scenario breast cancer measured as one of the dangerous health issues. An effective therapeutic class of drug known a …
The impact of hormones in autoimmune cutaneous diseases.
Lopes Almeida Gomes L, Werth AJ, Thomas P, Werth VP. Lopes Almeida Gomes L, et al. J Dermatolog Treat. 2024 Dec;35(1):2312241. doi: 10.1080/09546634.2024.2312241. Epub 2024 Feb 5. J Dermatolog Treat. 2024. PMID: 38317519 Free article. Review.
Search terms included 'contraceptives', 'pregnancy', 'hormone replacement', 'tamoxifen', and 'aromatase inhibitors'. RESULTS AND DISCUSSION: This comprehensive literature review shows that there remains considerable debate regarding the use of hormonal contraceptive …
Search terms included 'contraceptives', 'pregnancy', 'hormone replacement', 'tamoxifen', and 'aromatase inhibitors'. RESULTS A …
Protective role of exercise on breast cancer-related osteoporosis in women undergoing aromatase inhibitors: A narrative review.
Cerulli C, Moretti E, Grazioli E, Emerenziani GP, Murri A, Tranchita E, Minganti C, Di Cagno A, Parisi A. Cerulli C, et al. Bone Rep. 2024 Mar 25;21:101756. doi: 10.1016/j.bonr.2024.101756. eCollection 2024 Jun. Bone Rep. 2024. PMID: 38577250 Free PMC article. Review.
Despite the antitumor efficacy of hormone therapy, particularly of aromatase inhibitors, they cause long-term side effects, mainly bone density reduction. ...This narrative review aims to discuss studies on the effect of exercise on bone health in BC women undergoin …
Despite the antitumor efficacy of hormone therapy, particularly of aromatase inhibitors, they cause long-term side effects, ma …
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS. Slamon DJ, et al. J Clin Oncol. 2024 Mar 20;42(9):994-1000. doi: 10.1200/JCO.23.00137. Epub 2024 Jan 22. J Clin Oncol. 2024. PMID: 38252901 Free PMC article. Clinical Trial.
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer.
Guglielmi G, Del Re M, Gol LS, Bengala C, Danesi R, Fogli S. Guglielmi G, et al. Eur J Pharmacol. 2024 Apr 15;969:176424. doi: 10.1016/j.ejphar.2024.176424. Epub 2024 Feb 23. Eur J Pharmacol. 2024. PMID: 38402929 Free article. Review.
The therapeutic landscape of estrogen receptor (ER)-positive breast cancer includes endocrine treatments with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). ...
The therapeutic landscape of estrogen receptor (ER)-positive breast cancer includes endocrine treatments with aromatase inhibitors …
250 results